Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Renhe Pharmacy CoSZSE:000650 -1.29%83 Interest Coverage is 11,070.00 as of Jun. 2026, which is 329% above its 10-year median of 2,579.85. GuruFocus rates SZSE:000650 with a GF Score™ of 83/100 and a GF Value™ of ¥5.07 (Fairly Valued). The stock has 1 warning sign investors should review. Among 676 Drug Manufacturers companies, Renhe Pharmacy Co ranks better than 96.15% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Renhe Pharmacy Co's
Operating Income
for the
three
months ended in Jun. 2026 was ¥188 Mil. Renhe Pharmacy Co's Interest Expense for the
three
months ended in Jun. 2026 was ¥-0 Mil.
Renhe Pharmacy Co's interest coverage for the quarter that ended in Jun. 2026 was 11,070.00.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Renhe Pharmacy Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Renhe Pharmacy Co's Interest Coverage or its related term are showing as below:
SZSE:000650'
s Interest Coverage Range Over the Past 10 Years
Min: 567.34 Med: 2579.85 Max: 16194.7
Current: 8895.37
SZSE:000650's Interest Coverage is ranked better than 96.15% of 676
companies
in the Drug Manufacturers industry
Industry Median: 13
vs SZSE:000650: 8895.37
Renhe Pharmacy Co (SZSE:000650) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Renhe Pharmacy Co Interest Coverage Related Terms
Renhe Pharmacy Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Renhe Pharmacy Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Renhe Pharmacy Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renhe Pharmacy Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renhe Pharmacy Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Renhe Pharmacy Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renhe Pharmacy Co (SZSE:000650) has a Interest Coverage of 11,070.00 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Renhe Pharmacy Co and its competitors. This is 329% above median its historical median of 2,579.85. Over the past decade, Renhe Pharmacy Co's Interest Coverage has ranged from 567.34 to 16,194.70. According to the industry distribution chart, Renhe Pharmacy Co ranks #26 out of 676 companies in the Drug Manufacturers industry, placing it in the top 3.8%.
Is Renhe Pharmacy Co's Interest Coverage too high?
Renhe Pharmacy Co's current Interest Coverage of 11,070.00 is 329% above median its 10-year median of 2,579.85. Over the past 10 years, this metric has ranged from a low of 567.34 to a high of 16,194.70. The Drug Manufacturers industry median Interest Coverage is 13.00. Renhe Pharmacy Co's value of 11,070.00 is 85053.8% above this industry median. Based on the distribution chart, Renhe Pharmacy Co ranks #26 out of 676 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Renhe Pharmacy Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Renhe Pharmacy Co ranks #26 out of 676 companies for Interest Coverage. This places Renhe Pharmacy Co in the top 4% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 13.00. Renhe Pharmacy Co's value of 11,070.00 is 85053.8% above this benchmark. Historically, Renhe Pharmacy Co's own Interest Coverage has ranged from 567.34 to 16,194.70 over the past decade. While the company's 10-year median is 2,579.85 vs. the industry median of 13.00, Renhe Pharmacy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.00, based on 676 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renhe Pharmacy Co's current Interest Coverage of 11,070.00 is 85053.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Renhe Pharmacy Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renhe Pharmacy Co's current Interest Coverage is 11,070.00, which is 329% above median its own 10-year median of 2,579.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.07, compared to a current price of ¥5.37 — trading 5.9% above its estimated fair value. The current Interest Coverage is 11,070.00, which is 329% above median its 10-year median of 2,579.85 and 85053.8% above the Drug Manufacturers industry median of 13.00. Renhe Pharmacy Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current Interest Coverage is 11,070.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?
Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued.
The current stock price of ¥5.37 is trading 5.9% above its estimated GF Value™ of ¥5.07.
GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.
Key valuation signals for SZSE:000650:
Interest Coverage: 11,070.00 (329% above median its 10-year median of 2,579.85)
GF Value™: ¥5.07 vs. price of ¥5.37 (5.9% above fair value)
Industry Position: 85053.8% above the Drug Manufacturers median (#26 of 676)
No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
83GF Score
Get the complete analysis for SZSE:000650
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000650 has been successfully added to your 
